arrow
A

Andrzej Jakubowiak

university of chicago
H指数:67
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma

达鲁卡替ogene autoleucel在复发/难治性多发性骨髓瘤患者中的I期试验的疗效和安全性

2026-05-270
PRE
Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent

三药类暴露的复发/难治性多发性骨髓瘤中塔奎他单抗与真实世界医生选择治疗的比较疗效:MonumenTAL-1与LocoMMotion/MoMMent的更新分析

2025-11-280
OAAI
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma

多发性骨髓瘤患者接受及未接受来那度胺维持治疗时克隆性造血的演变

Leukemia
IF13.4
2025-07-160
OAAI
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma
2024-10-250
OAAI
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

多发性骨髓瘤的综合分子谱分析可确定精细的拷贝数和表达亚型

2024-08-192
OAAI
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
2024-07-080
OAAI
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone
2024-05-141
OA
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
2024-04-227
OAAI
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN
2024-04-150
OAAI
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

Elranatamab治疗复发或难治性多发性骨髓瘤: MagnetisMM-1的1期临床试验

2023-10-0246
OAAI
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
2023-10-0154
PRE
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials

含达雷妥尤单抗和来那度胺的四联体诱导疗法在新诊断的多发性骨髓瘤中的干细胞动员产量: MASTER和GRIFFIN试验的发现

2023-03-0133
OAAI
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
2023-02-170
OA
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
2022-12-2212
OAAI
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study
2022-12-0121
PRE